Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sino Biopharmaceutical Limited - SIC # 740 -
Ticker
Exchange
SIC #
Website
Latest Ticker
SBHMY
Over the counter
740
www.sbpgroup.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sino Biopharmaceutical Limited
GSK plc (GSK) Announces Japan’s Expanded Eligible Population for Arexvy
- May 28th, 2026 11:37 pm
GSK’s Expanded Arexvy Label And Deals Add Context To Valuation Gap
- May 22nd, 2026 6:24 pm
GSK China Hepatitis B Alliance Puts Bepirovirsen And Valuation In Focus
- May 12th, 2026 3:09 am
European Stocks Mixed in Monday Trading; Defense, Luxury Goods Stocks Drop, Mining Shares Rise
- May 11th, 2026 9:54 am
GSK cuts deal with Sino to broaden reach of hepatitis B drug
- May 11th, 2026 5:56 am
Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal
- Mar 4th, 2026 12:02 pm
Weighing Sino Biopharmaceutical (SEHK:1177) After Strong One Year Share Price Run
- Jan 15th, 2026 7:10 pm
Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs
- Nov 24th, 2025 5:42 pm
MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model
- Nov 9th, 2025 11:18 pm
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
- Oct 30th, 2025 4:30 am
What Do Recent Swings and Cash Flow Growth Mean for Sino Biopharm’s 2025 Value?
- Oct 19th, 2025 4:08 pm
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
- Oct 16th, 2025 2:05 pm
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
- Jul 15th, 2025 9:44 am
Cancer drugmaker LaNova to sell to China’s Sino Biopharm
- Jul 15th, 2025 5:08 am
Scroll